AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12640530 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-week group
Number of subjects: 51
Study 16862613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh
Number of subjects: 600
Study 16862613 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 600
Study 10553857 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.0 mg/kg)
Number of subjects: 172
Study 10553857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.20 mg/kg)
Number of subjects: 172
Study 10553857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 172
Study 10553857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 172
Study 10553857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg/kg)
Number of subjects: 172
Study 10553857 — intervention group
Group type: COMPARATOR
Intervention: Overall intubating conditions (all groups)
Number of subjects: 172
Study 8916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1.0 MAC)
Number of subjects: 30
Study 8916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.0 MAC)
Number of subjects: 30
Study 8916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (0.5 MAC)
Number of subjects: 30
Study 8916815 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC)
Number of subjects: 30
Study 8916815 — intervention group
Group type: COMPARATOR
Intervention: Propofol (control group)
Number of subjects: 30
Study 1677901 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 30
Study 1677901 — intervention group
Group type: COMPARATOR
Intervention: 60 mg terfenadine twice daily
Number of subjects: 30
Study 6349950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 103
Study 6349950 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole and Gentamicin
Number of subjects: 103
Study 28382883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga classes
Number of subjects: 122
Study 28382883 — intervention group
Group type: COMPARATOR
Intervention: Health education classes (HLW)
Number of subjects: 122
Study 27332391 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily teleconsultation for one week between hospital-based telenurses and patients with severe COPD
Number of subjects: 0
Study 27332391 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 25058084 — intervention group
Group type: COMPARATOR
Intervention: Digital mammography
Number of subjects: 454850
Study 25058084 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mammography + tomosynthesis
Number of subjects: 454850
Study 22336194 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative physiotherapy program, carried out twice a day for three weeks (week 34, 35, 36 postmenstrual age).
Number of subjects: 150
Study 22336194 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care (control group).
Number of subjects: 150
Study 19171294 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Outpatient Intensive Management Program (DOIMP)
Number of subjects: 49
Study 19171294 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes education
Number of subjects: 49
Study 17239873 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative resectoscopy
Number of subjects: 100
Study 17239873 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrode excision
Number of subjects: 100
Study 15645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 0
Study 15645313 — intervention group
Group type: EXPERIMENTAL
Intervention: New data sets
Number of subjects: 0
Study 15645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Historic data sets
Number of subjects: 0
Study 15645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk estimates at low exposures
Number of subjects: 0
Study 12221462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative local irradiation
Number of subjects: 44
Study 12221462 — intervention group
Group type: COMPARATOR
Intervention: No local graft irradiation (Control)
Number of subjects: 44
Study 9436880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.3%)
Number of subjects: 0
Study 9436880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (0.3%)
Number of subjects: 0
Study 9436880 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine (5%)
Number of subjects: 0
Study 7940651 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung-12 administered in the morning
Number of subjects: 79
Study 7940651 — intervention group
Group type: COMPARATOR
Intervention: Zung-12 administered in the afternoon
Number of subjects: 79
Study 7940651 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with lower education
Number of subjects: 79
Study 7940651 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 79
Study 7940651 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects scoring above the cutting point
Number of subjects: 79
Study 2573679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen, hypoxic cell radiosensitizers, modification of the oxygen‐unloading capacity of haemoglobin, hyperthermia, bio‐reductive drugs
Number of subjects: 0
Study 2573679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic cell radiosensitizers and other agents
Number of subjects: 0
Study 2573679 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed analysis of individual tumours and patients' parameters
Number of subjects: 0
Study 31669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 50 μg
Number of subjects: 183
Study 31669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 100 μg
Number of subjects: 183
Study 31669562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 31669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (both doses)
Number of subjects: 183
Study 31669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 183
Study 31839012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurture and Play (NaP) intervention group (n = 24)
Number of subjects: 45
Study 31839012 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study 29046305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 23
Study 29046305 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 23
Study 26454935 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system developed by the authors (experimental group)
Number of subjects: 106
Study 26454935 — intervention group
Group type: COMPARATOR
Intervention: Image-free navigation system (control group)
Number of subjects: 106
Study 24048291 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol potassium chloride for 6 weeks)
Number of subjects: 40
Study 24048291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21182390 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - provided with reading material and images to draw and label surface anatomy.
Number of subjects: 144
Study 21182390 — intervention group
Group type: COMPARATOR
Intervention: Group B - provided with the same reading material but answered short-answer questions.
Number of subjects: 144
Study 20876406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 160
Study 20876406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 17413115 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified khichdi
Number of subjects: 516
Study 17413115 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified khichdi
Number of subjects: 516
Study 15620918 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 104
Study 15620918 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with white matter disease
Number of subjects: 104
Study 15620918 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation
Number of subjects: 104
Study 15620918 — intervention group
Group type: EXPERIMENTAL
Intervention: No white matter disease
Number of subjects: 104
Study 12380661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (50-100 microg/h)
Number of subjects: 19
Study 12380661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 19
Study 9928729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (9900 micromol or 300,000 IU)
Number of subjects: 40
Study 9928729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7579846 — intervention group
Group type: COMPARATOR
Intervention: Conventional hypothermic CPB with rewarming
Number of subjects: 30
Study 7579846 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol where brain temperature is raised only to 34 degrees C at the time of separation from CPB
Number of subjects: 30
Study 2292548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ciprofloxacin
Number of subjects: 40
Study 2292548 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin and gentamicin (control)
Number of subjects: 40
Study 6268498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hametum Salbe
Number of subjects: 116
Study 6268498 — intervention group
Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 116
Study 30651324 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNB1020 (engineered E. coli Nissle 1917)
Number of subjects: 52
Study 28422535 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) (0.9% sodium chloride)
Number of subjects: 20
Study 28422535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (RA)
Number of subjects: 20
Study 25868467 — intervention group
Group type: EXPERIMENTAL
Intervention: no heat stress-euhydrated
Number of subjects: 12
Study 25868467 — intervention group
Group type: EXPERIMENTAL
Intervention: heat stress-euhydrated
Number of subjects: 12
Study 25868467 — intervention group
Group type: EXPERIMENTAL
Intervention: no heat stress-dehydrated
Number of subjects: 12
Study 25868467 — intervention group
Group type: EXPERIMENTAL
Intervention: heat stress-dehydrated
Number of subjects: 12
Study 22694918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention consisting of a lecture and group work (1.5h)
Number of subjects: 1866
Study 22694918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 1866
Study 22694918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1866
Study 21127898 — intervention group
Group type: EXPERIMENTAL
Intervention: Static squat with WBV
Number of subjects: 12
Study 21127898 — intervention group
Group type: EXPERIMENTAL
Intervention: Static squat without WBV (no-WBV)
Number of subjects: 12
Study 21127898 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 12
Study 19441968 — intervention group
Group type: EXPERIMENTAL
Intervention: Filial Therapy and Kinder Training (play-based interventions)
Number of subjects: 0
Study 19441968 — intervention group
Group type: COMPARATOR
Intervention: Waiting-control group
Number of subjects: 0
Study 17868732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily for 4 weeks, followed by 2 weeks off drug per treatment cycle)
Number of subjects: 106
Study 17868732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 106
Study 15500630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to normal office dust at 136 microg/m3
Number of subjects: 24
Study 15500630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to normal office dust at 390 microg/m3
Number of subjects: 24
Study 15500630 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 24
Study 15500630 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed effect on peak expiratory flow
Number of subjects: 24
Study 11584378 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antigen recombinant vaccine (20-microg dose)
Number of subjects: 925
Study 11584378 — intervention group
Group type: COMPARATOR
Intervention: Single-antigen vaccine (S only)
Number of subjects: 925
Study 9398000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 11
Study 9398000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7864561 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg, 2 daily infusions for 8 days)
Number of subjects: 37
Study 7864561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2905240 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg twice daily
Number of subjects: 295
Study 2905240 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 295
Study 31978354 — intervention group
Group type: EXPERIMENTAL
Intervention: VXA‐A1.1 (1011 infectious units, orally)
Number of subjects: 179
Study 31978354 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV (full human dose, intramuscular)
Number of subjects: 179
Study 31978354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 179
Study 31978354 — intervention group
Group type: EXPERIMENTAL
Intervention: VXA‐A1.1
Number of subjects: 179
Study 31978354 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 179
Study 31978354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 30232107 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who understood their treatment intent
Number of subjects: 282
Study 30232107 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not understand their treatment intent
Number of subjects: 282
Study 27871601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 68
Study 27871601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 68
Study 27871601 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.1 mL/kg)
Number of subjects: 68
Study 24255934 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing (Coepak(®) ) for 7 days
Number of subjects: 24
Study 24255934 — intervention group
Group type: COMPARATOR
Intervention: No periodontal dressing (Control)
Number of subjects: 24
Study 22488402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of MetSx
Number of subjects: 74
Study 22488402 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis of individual cardiovascular risk factors
Number of subjects: 74
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk men (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk women (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk younger patients (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk older patients (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who agreed to CC (perceived benefit from CC)
Number of subjects: 237
Study 20931097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were disagreeable or made no comment (perceived benefit from CC)
Number of subjects: 237
Study 18230968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (200 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Number of subjects: 33
Study 18230968 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks and 200 g/day for 2 weeks)
Number of subjects: 33
Study 15896564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15896564 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 28
Study 15896564 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 28
Study 12244361 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (radio forum)
Number of subjects: 70
Study 12244361 — intervention group
Group type: COMPARATOR
Intervention: Group B (non-organized listening)
Number of subjects: 70
Study 11382854 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Pharyngeal Constrictor Muscles (MPCM) evaluation in OSA patients
Number of subjects: 22
Study 11382854 — intervention group
Group type: COMPARATOR
Intervention: Medium Pharyngeal Constrictor Muscles (MPCM) evaluation in non-OSA patients
Number of subjects: 22
Study 11382854 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy of Vastus Lateralis Muscle (VLM) in OSA patients
Number of subjects: 22
Study 11382854 — intervention group
Group type: COMPARATOR
Intervention: Needle biopsy of Vastus Lateralis Muscle (VLM) in non-OSA patients
Number of subjects: 22
Study 7634550 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plasma exchange
Number of subjects: 22
Study 7634550 — intervention group
Group type: COMPARATOR
Intervention: Cascade filtration
Number of subjects: 22
Study 2515825 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (10 mg/kg)
Number of subjects: 41
Study 758131 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU; 300 mg/day)
Number of subjects: 133
Study 758131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 31860742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene or scaling and root planning ± placebo or polyunsaturated fatty acids fish oil
Number of subjects: 81
Study 31542771 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding milk feeds (for 4 hours before, during and for 4 hours after red cell transfusions)
Number of subjects: 0
Study 31542771 — intervention group
Group type: COMPARATOR
Intervention: Continuing milk feeds (before, during and after red cell transfusions)
Number of subjects: 0
Study 28321995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Garcinia mangostana L. pericarp gel (MGA) as local drug delivery with scaling and root planing (SRP)
Number of subjects: 50
Study 28321995 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel with scaling and root planing (SRP)
Number of subjects: 50
Study 25795452 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg QD)
Number of subjects: 34
Study 25795452 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg QD)
Number of subjects: 34
Study 23442248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1102
Study 23442248 — intervention group
Group type: COMPARATOR
Intervention: Live vaccine as the most recent vaccination
Number of subjects: 1102
Study 23442248 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine as the most recent vaccination
Number of subjects: 1102
Study 23442248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 1102
Study 23442248 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with infection excluded
Number of subjects: 1102
Study 22024188 — intervention group
Group type: EXPERIMENTAL
Intervention: InFoQI program (intervention arm)
Number of subjects: 0
Study 22024188 — intervention group
Group type: COMPARATOR
Intervention: Basic NICE registry feedback (control arm)
Number of subjects: 0
Study 19302699 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTs derived from time-to-event outcomes
Number of subjects: 734
Study 19302699 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTs derived from binary outcomes
Number of subjects: 734
Study 19302699 — intervention group
Group type: EXPERIMENTAL
Intervention: NNTs reporting articles
Number of subjects: 734
Study 16427389 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 microg/kg
Number of subjects: 399
Study 16427389 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 399
Study 16427389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 15605806 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 51
Study 15605806 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radiotherapy (non-irradiated)
Number of subjects: 51
Study 11574493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for three months
Number of subjects: 30
Study 11574493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9762741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine medial branch injections
Number of subjects: 18
Study 9762741 — intervention group
Group type: COMPARATOR
Intervention: saline medial branch injections
Number of subjects: 18
Study 7909099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at 0.4 g/kg body weight
Number of subjects: 82
Study 7909099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.4% albumin)
Number of subjects: 82